ME 1111

Drug Profile

ME 1111

Alternative Names: ME-1111

Latest Information Update: 14 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Meiji Seika Pharma
  • Class Antifungals
  • Mechanism of Action Succinate cytochrome c oxidoreductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Onychomycosis

Most Recent Events

  • 01 Feb 2018 Phase-II clinical trials in Onychomycosis in Japan (Topical) (JapicCTI183840)
  • 01 Feb 2018 Meiji Seika Pharma plans a phase II trial for Onychomycosis in Japan (JapicCTI183840)
  • 18 Apr 2016 ME 1111 is still in phase II trials for Onychomycosis in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top